search
Back to results

Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease

Primary Purpose

Huntington's Disease

Status
Completed
Phase
Locations
Study Type
Observational
Intervention
Sponsored by
National Center for Research Resources (NCRR)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Huntington's Disease focused on measuring Huntington's disease, neurologic and psychiatric disorders, rare disease

Eligibility Criteria

0 Years - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Documented family history of Huntington's disease (HD) Symptomatic HD: chorea required At-risk for HD: no detectable systemic or oculomotor abnormality Age-matched control subjects No history of inherited neurological disease No general or neurologic abnormality --Prior/Concurrent Therapy-- At least 4 weeks since other HD treatment, e.g.: Haloperidol Benzodiazepine Other tranquilizers or neuroleptics --Patient Characteristics-- No pregnant women

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    February 24, 2000
    Last Updated
    June 23, 2005
    Sponsor
    National Center for Research Resources (NCRR)
    Collaborators
    National Institute of Neurological Disorders and Stroke (NINDS), University of California, Los Angeles
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00004753
    Brief Title
    Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease
    Study Type
    Observational

    2. Study Status

    Record Verification Date
    December 2001
    Overall Recruitment Status
    Completed
    Study Start Date
    August 1993 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    National Center for Research Resources (NCRR)
    Collaborators
    National Institute of Neurological Disorders and Stroke (NINDS), University of California, Los Angeles

    4. Oversight

    5. Study Description

    Brief Summary
    OBJECTIVES: I. Correlate clinical outcome with cerebral glucose metabolism in patients with Huntington's disease (HD) and their at-risk relatives. II. Evaluate the efficacy of cerebral glucose metabolism in observing the pathophysiologic development of HD, monitoring responses to experimental therapy, and predicting HD genotype. III. Identify, define, and describe the natural history of pathophysiologic lesions in HD. IV. Characterize the genotypic and phenotypic expression of the HD gene.
    Detailed Description
    PROTOCOL OUTLINE: Participants are screened for Huntington's disease, including cerebral glucose metabolism assessment and genetic testing. Studies include a detailed family history and neurologic, psychometric, and neurobehavioral evaluations. Imaging includes positron emission tomography with fluorodeoxyglucose and brain magnetic resonance imaging. A genotype assessment is performed; genetic results are not disclosed to patients or relatives.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Huntington's Disease
    Keywords
    Huntington's disease, neurologic and psychiatric disorders, rare disease

    7. Study Design

    Enrollment
    90 (false)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    0 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Documented family history of Huntington's disease (HD) Symptomatic HD: chorea required At-risk for HD: no detectable systemic or oculomotor abnormality Age-matched control subjects No history of inherited neurological disease No general or neurologic abnormality --Prior/Concurrent Therapy-- At least 4 weeks since other HD treatment, e.g.: Haloperidol Benzodiazepine Other tranquilizers or neuroleptics --Patient Characteristics-- No pregnant women
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    John C. Mazziotta
    Organizational Affiliation
    University of California, Los Angeles
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Learn more about this trial

    Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease

    We'll reach out to this number within 24 hrs